KDR and neoplasm: In the clinic, there are several approaches targeting angiogenesis and ECs for anti‐tumor therapy: 1) binding the circulating vascular endothelial growth factor (VEGF) by the neutralizing monoclonal antibody, 2) blocking the tyrosine kinase activity of VEGFRs by small molecules inhibitors, and 3) binding the VEGFR‐2 by the monoclonal antibody.[83]